CTX 1301

Drug Profile

CTX 1301

Alternative Names: CTX-1301

Latest Information Update: 11 Jul 2017

Price : $50

At a glance

  • Originator Cingulate Therapeutics
  • Developer Bio-Images Drug Delivery; Cingulate Therapeutics
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Attention-deficit hyperactivity disorder

Most Recent Events

  • 10 Jul 2017 Cinagulate completes a phase I trial in Attention-deficit hyperactivity disorder (In volunteers) in Scotland (PO)
  • 31 May 2017 Bio-images Drug Delivery has patent protection for OralogiK™ in USA, European union and Japan
  • 31 May 2017 Cingulate Therapeutics plans to file an IND application with the US FDA for Attention deficit/hyperactivity disorder
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top